Treatment Tips in Chronic Lymphocytic Leukemia Treatment Tips in Chronic Lymphocytic Leukemia
A conversation with CLL specialists Drs Anthony Mato and Lindsey Roeker about the novel agents acalabrutinib, obinutuzumab, and venetoclax.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
New Score Predicts When Patients With CLL Should Start Treatment New Score Predicts When Patients With CLL Should Start Treatment
Patients with chronic lymphocytic leukemia are initially followed with active surveillance; a new prognostic score helps the decision-making process of when they should start treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Initial Ibrutinib Dose and Its Modification Do Not Affect Survival in Patients with CLL
Researchers found that in patients with chronic lymphocytic leukemia receiving commercial ibrutinib, initial dose and dose modification during therapy did not appear to impact event-free survival or overall survival. (Source: CancerNetwork)
Source: CancerNetwork - April 6, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Ibrutinib Interruption Tied to Worse Outcomes in CLL Ibrutinib Interruption Tied to Worse Outcomes in CLL
In a retrospective analysis, patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib had worse outcomes if the dosing was interrupted for any reason.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 1, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile of the...
Source: Roche Investor Update - March 23, 2020 Category: Pharmaceuticals Source Type: news
Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile of the...
Source: Roche Media News - March 23, 2020 Category: Pharmaceuticals Source Type: news
Researchers in Singapore find common therapeutic vulnerability for a genetically diverse and deadly
(Duke-NUS Medical School) Scientists and clinicians from Duke-NUS Medical School, the Agency for Science, Technology and Research's (A*STAR's) Genome Institute of Singapore (GIS), and the Singapore General Hospital (SGH), have devised a novel drug combination that could treat a particularly deadly form of leukaemia, known as blast crisis (BC) chronic myeloid leukaemia (CML). The team has also developed strategies that may identify patients with early stage or chronic phase (CP) CML who are at increased risk of developing BC, and potentially preventing disease progression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2020 Category: Cancer & Oncology Source Type: news
AbbVie Receives European Commission Approval of VENCLYXTO(R) Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
VENCLYXTO® plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the European Commission (EC) for patients with previously untreated chronic lymphocytic leukemia (CLL)
Approval is based on data from the Pha... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 12, 2020 Category: Pharmaceuticals Source Type: news
European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
Basel, 12 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).“Venclyxto plus Gazyvaro is the first fixed-duration, chemotherapy-free treatment option that has been shown to help patients with untreated chronic lymphocytic leukaemia live longer without their disease progressing,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This is an im...
Source: Roche Media News - March 12, 2020 Category: Pharmaceuticals Source Type: news
European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
Basel, 12 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).“Venclyxto plus Gazyvaro is the first fixed-duration, chemotherapy-free treatment option that has been shown to help patients with untreated chronic lymphocytic leukaemia live longer without their disease progressing,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This is an im...
Source: Roche Investor Update - March 12, 2020 Category: Pharmaceuticals Source Type: news
Jennifer A. Woyach, MD, on Frontline Treatments for Patients with CLL
The associate professor of hematology spoke with CancerNetwork ®about frontline treatments available for patients with chronic lymphocytic leukemia and the toxicities present for these treatments. (Source: CancerNetwork)
Source: CancerNetwork - March 11, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
What Causes Neutropenia?
Discussion
Neuropenia is defined as a neutrophil count < 1500/µL. It is classified as mild from 1000-1500/µL, moderate from 500-1000/µL, and severe if < 500/µL.
It is not uncommonly seen in the setting of acute self-limited infections, and with re-testing returns to normal. It is also not uncommon at certain ages, such as perinatally, especially in premature infants (up to 6%) . It is also common in certain ethnic groups particularly African American or Arabic populations where up to 10% of the children may have mild neutropenia which does not cause clinical disease. The overall prevalence a...
Source: PediatricEducation.org - March 2, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Invasive Aspergillosis in the Setting of Ibrutinib Therapy for Chronic Lymphocytic Leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 28, 2020 Category: Respiratory Medicine Authors: MeganB Source Type: news
Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “While we contin...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
